Biomarkers of vascular dysfunction in children infected with human immunodeficiency virus-1

Journal of Acquired Immune Deficiency Syndromes

Volumn 55, Issue 2, 2010, Pages 182-188

  Miller, Tracie L ^a   Somarriba, Gabriel ^a   Orav, E John ^a   Mendez, Armando J ^a   Neri, Daniela ^a   Schaefer, Natasha ^a   Forster, Lourdes ^b   Goldberg, Ronald ^a   Scott, Gwendolyn B ^a   Lipshultz, Steven E ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Biomarkers; Cardiovascular risk factors; Children; HIV AIDS; Vascular dysfunction

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; CCL2 PROTEIN, HUMAN;

ADOLESCENT; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CD4 LYMPHOCYTE COUNT; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; VASCULAR DISEASE; VIRUS LOAD; WAIST HIP RATIO; BLOOD; BLOOD VESSEL; CASE CONTROL STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY;

ADOLESCENT; BIOLOGICAL MARKERS; BLOOD VESSELS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CCL2; CHILD; E-SELECTIN; FEMALE; FIBRINOGEN; HIV INFECTIONS; HIV-1; HUMANS; LEPTIN; MALE; MULTIVARIATE ANALYSIS; P-SELECTIN; VASCULAR CELL ADHESION MOLECULE-1; WAIST-HIP RATIO;

EID: 77957311960     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181e222c9     Document Type: Article

References (48)

1. Laufer M, Scott GB. Medical management of HIV disease in children. Pediatr Clin North Am. 2000;47:127-153.
2. Carr A, Samaras K, Chisholm DJ, et al. Abnormal fat distribution and use of protease inhibitors. Lancet. 1998;351:1736.
3. Friis-Moller N, Sabin CA,Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
4. Miller TL, Orav EJ, Lipshultz SE, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr. 2008;153:491-497.
5. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
6. Ikonomidis I, Stamatelopoulos K, Lekakis J, et al. Inflammatory and noninvasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis. 2008;199:3-11.
7. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000:8:1-27.
8. Caldwell MB, Oxtoby MJ, Simonds RJ, et al. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill Summ. 1994;43:1-10.
9. Margulies L,HorlickM, Thornton JC, et al. Reproducibility of pediatricwhole body bone and body composition measures by dual-energy X-ray absorptiometry using the GE Lunar Prodigy. J Clin Densitom. 2005;8:298-304.
10. National Health and Nutrition Examination Survey III Body Measurements (Anthropometry). 1988. Available at: http://www.cdc.gov/nchs/nhanes/ nh3rrm.htm. Accessed May 1, 2009.
11. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA. 1998;280:72-77.
12. Teitel JM, Shore A, Read SE, et al. Immune function of vascular endothelial cells is impaired by HIV. J Infect Dis. 1989;160:551-552.
13. Dhawan S, Puri RK, Kumar A, et al. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood. 1997;90:1535-1544.
14. Fisher SD, Miller TL, Lipshultz SE. Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis. 2006;185:1-11.
15. Bitnun A, Sochett E, Dick PT, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virusinfected children. J Clin Endocrinol Metab. 2005;90:168-174.
16. Miller TL. Nutritional aspects of HIV-infected children receiving highly active antiretroviral therapy. AIDS. 2003;17(Suppl 1):S130-S140.
17. Arpadi SM, Bethel J, Horlick M, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS. 2009;23: 1501-1509.
18. Miller TL, Grant YT, Almeida DN, et al. Cardiometabolic disease in human immunodeficiency virus-infected children. J Cardiometab Syndr. 2008;3:98-105.
19. Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107:E77.
20. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
21. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48-62. (Pubitemid 40075680)
22. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
23. Martinez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis. 2009;22:28-34.
24. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92: 2506-2512.
25. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
26. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997;96:4219-4225.
27. Grinspoon SK, Grunfeld C, Kotler DP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008;118:198-210.
28. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radic Biol Med. 1995;19:523-528.
29. Lo J, Grinspoon S. Cardiovascular disease in HIV-infected patients: does HIV infection in and of itself increase cardiovascular risk? Curr Opin HIV AIDS. 2008;3:207-213.
30. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009;51:268-273.
31. de Larranaga GF, Bocassi AR, Puga LM, et al. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb Res. 2003;110:93-98.
32. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185:456-462.
33. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med. 1999;5: 997-1103
34. Cota-Gomez A, Flores NC, Cruz C, et al. The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem. 2002;277:14390-14399.
35. Vicenzi E, Alfano M, Ghezzi S, et al. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol. 2000;68:405-412.
36. Zhong DS, Lu XH, Conklin BS, et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22:1560-1566.
37. Jiang B, Hebert VY, Li Y, et al. HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol. 2007; 224:60-71.
38. Hebert VY, Crenshaw BL, Romanoff RL, et al. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation. Cardiovasc Toxicol. 2004;4:117-131.
39. Chen C, Lu XH, Yan S, et al. HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun. 2005;335:874-882.
40. Mondal D, Pradhan L, Ali M, et al. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol. 2004;4:287-302.
41. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab. 2004;286:E261-E271.
42. de Gaetano Donati K, Rabagliati R, Tumbarello M, et al. Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. AIDS. 2003;17:765-768.
43. Bonnet D, Aggoun Y, Szezepanski I, et al. Arterial stiffness and endothelial dysfunction in HIV-infected children. AIDS. 2004;18:1037-1041.
44. Giuliano Ide C, de Freitas SF, de Souza M, et al. Subclinic atherosclerosis and cardiovascular risk factors in HIV-infected children: PERI study. Coron Artery Dis. 2008;19:167-172.
45. Charakida M, Donald AE, Green H, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation. 2005;112:103-109.
46. McComsey GA, O'Riordan M, Hazen SL, et al. Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS. 2007;21:921-927.
47. Perez-Atayde AR, Kearney DI, Bricker JT, et al. Cardiac, aortic, and pulmonary arteriopathy in HIV-infected children: the Prospective P2C2 HIV Multicenter Study. Pediatr Dev Pathol. 2004;7:61-70.
48. Miller T, Jacobson D, Mendez A, et al. Biomarkers of vascular dysfunction in HIV-infected children with and without hyperlipidemia. Presented at: 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009); February 8-11, 2009; Montreal, Canada. 2009. Abstract #917.